

Sr.	Title	PROJECT	Application No.	Patent No.	Country
1	Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	P000105723	026300	Argentina
2	Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses.	P-IV (AGE Breaker)	P010101548	031564	Argentina
3	Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	31376/01	766824	Australia
4	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	AU5994299	769940	Australia
5	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	9913746-1	9913746-1	Brazil
6	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	2344144	2344144	Canada
7	Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	2341949	2341949	Canada
8	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	99811038.8	364772	China
9	Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	ZL 01112413.X	153926	China
10	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	2001-1033	291789	Czech
11	Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	2001-1032	303214	Czech
12	Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	01201057.5	1243581	Europe
13	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	99973986.5	1222171	Europe

14	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	2105889.1	1044335	Hongkong
15	Pyridinium compounds useful for the treatment of age-related diseases	P-IV (AGE Breaker)	02107559.6	1045996	Hongkong
16	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	P0104116	227523	Hungary
17	Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	828/CAL/99	250728	India
18	Novel compounds for the management of aging-related and diabetic vascular complications, and therapeutic uses thereof	P-IV (AGE Breaker)	843/CAL/99	208773	India
19	Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	604Cal2001	214276	India
20	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	W00200200782	0 019095	Indonesia
21	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	2001-528154	4068843	Japan
22	Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	2001-81819	4471141	Japan
23	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	PA/a/2002/003495	228607	Mexico
24	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	P.348327	211112	Poland
25	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	2001107007	2215000	Russia
26	Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	09/598410	6462057	USA
27	Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	10/214704	6624178	USA

28	Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	09/939702	6608094	USA
29	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	99973986.5	(Validation of EP1222171)	Belgium
30	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	FI/EP1222171	(Validation of EP1222171)	Finland
31	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	3049124	(Validation of EP1222171)	Greece
32	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	99973986.5	(Validation of EP1222171)	Germany
33	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	99973986.5	(Validation of EP1222171)	Ireland
34	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	99973986.5	(Validation of EP1222171)	Italy
35	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	99973986.5	(Validation of EP1222171)	Portugal
36	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	99973986.5	(Validation of EP1222171)	Switzerland
37	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	99973986.5	(Validation of EP1222171)	Sweden
38	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	99973986.5	(Validation of EP1222171)	Spain
39	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	E260256	(Validation of EP1222171)	Austria

40	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	DK/EP1222171	(Validation of EP1222171)	Denmark
41	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	99973986.5	(Validation of EP1222171)	France
42	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	9997386.5	(Validation of EP1222171)	United Kingdom
43	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	99973986.5	(Validation of EP1222171)	Netherlands
44	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	1222171	(Validation of EP 1222171)	Cyprus
45	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	1222171	(Validation of EP1222171)	Luxembourg
46	Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof	P-IV (AGE Breaker)	1222171	(Validation of EP1222171)	Monaco
47	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	E299496	(Validation of EP1243581)	Austria
48	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	1243581	(Validation of EP1243581)	Belgium
49	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	CY05/1101219	(Validation of EP1243581)	Cyprus
50	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	1243581	(Validation of EP1243581)	Denmark
51	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	FI/EP 1243581	(Validation of EP1243581)	Finland
52	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	1243581	(Validation of EP1243581)	France
53	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	DE60111919.3-08	(Validation of EP1243581)	Germany

54	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	1243581	(Validation of EP1243581)	United Kingdom
55	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	20050402933	(Validation of EP1243581)	Greece
56	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	1243581	(Validation of EP1243581)	Ireland
57	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	30297/BE/2005	(Validation of EP1243581)	Italy
58	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	1243581	(Validation of EP1243581)	Luxembourg
59	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	1243581	(Validation of EP1243581)	Monaco
60	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	1243581	(Validation of EP1243581)	Netherlands
61	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	1243581	(Validation of EP1243581)	Portugal
62	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	1243581	(Validation of EP1243581)	Spain
63	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	01201057.5	(Validation of EP1243581)	Sweden
64	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	1243581	(Validation of EP1243581)	Switzerland
65	Novel compounds for the management of again related and diabetic vascular complications, process for their preparation and therapeutic uses	P-IV (AGE Breaker)	1243581	(Validation of EP1243581)	Turkey
66	Novel compounds for the management of aging related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof	P-IV (Het)	10116135	72,23,777	USA
67	Heterocyclic compounds for aging-related and diabetic vascular complications	P-IV (Het)	01174/KOLNP/2003	219920	India
68	Heterocyclic compounds for aging-related and diabetic vascular complications	P-IV (Het)	2722547.3	1373263	Europe
69	Heterocyclic compounds for aging-related and diabetic vascular complications	P-IV (Het)	2002-583424	4485744	Japan
70	Heterocyclic compounds for aging-related and diabetic vascular complications	P-IV (Het)	2806980.3	2806980.3	China

71	Heterocyclic compounds for ageing-related and diabetic vascular complications	P-IV (Het)	2003128076	2291154	Russia
72	Heterocyclic compounds for aging-related and diabetic vascular complications	P-IV (Het)	2002253432	2002253432	Australia
73	Heterocyclic compounds for aging-related and diabetic vascular complications	P-IV (Het)	7012877/2003	785109	Korea
74	Heterocyclic compounds for aging-related and diabetic vascular complications	P-IV (Het)	W00200301712	0 018707	Indonesia
75	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	PA/a/2003/ 008089	240491	Mexico
76	Heterocyclic compounds for aging-related and diabetic vascular complications	P-IV (Het)	24,39,593	2439593	Canada
77	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	2003/6370	2003/6370	South Africa
78	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	04104243.3	1061234	Hongkong
79	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	P200501365	Validation of EP1373263	Albania
80	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	E280766	Validation of EP1373263	Austria
81	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	01373263	Validation of EP1373263	Belgium
82	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	CY 05 / 1100144	Validation of EP1373263	Cyprus
83	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	01373263	Validation of EP1373263	Denmark
84	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	FI/EP 1373263	Validation of EP1373263	Finland
85	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	01373263	Validation of EP1373263	France
86	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	60201740-8	Validation of EP1373263	Germany
87	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	01373263.0	Validation of EP1373263	Britain
88	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	20050400288.0	Validation of EP1373263	Greece
89	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	01373263.0	Validation of EP1373263	Ireland
90	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	20295/BE/05	Validation of EP1373263	Italy
91	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	01373263.0	Validation of EP1373263	Latva
92	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	01373263.0	Validation of EP1373263	Lithuania
93	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	01373263.0	Validation of EP1373263	Netherlands

94	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	01373263.0	Validation of EP1373263	Portugal
95	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	1002366	Validation of EP1373263	Romania
96	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	P-200230069	Validation of EP1373263	Slovenia
97	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	02722547-3	Validation of EP1373263	Spain
98	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	01373263	Validation of EP1373263	Sweden
99	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	01373263	Validation of EP1373263	Switzerland / Liechtenstein
100	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	01373263	Validation of EP1373263	Switzerland / Liechtenstein
101	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	Validation of European Patent no. 1373263	Validation of EP1373263	Turkey
102	Heterocyclic compounds for aging related and diabetic vascular complications	P-IV (Het)	Validation of European Patent no. 1373263	Validation of EP1373263	Luxembourg
103	Pharmaceutical composition comprising a combination of dextro and laevo isomers of sotalol	(P-I) (TRC-303)	22960/99	761521	Australia
104	Pharmaceutical composition comprising a combination of dextro and laevo isomers of sotalol	(P-I) (TRC-303)	2348882	2348882	Canada
105	Pharmaceutical composition comprising a combination of dextro and laevo isomers of sotalol	(P-I) (TRC-303)	99813639.5	155281	China
106	Pharmaceutical composition comprising a combination of dextro and laevo isomers of sotalol	(P-I) (TRC-303)	99902781.6	1146865	Europe
107	Pharmaceutical composition comprising a combination of dextro and laevo isomers of sotalol	(P-I) (TRC-303)	P0104175	224033	Hungary
108	Pharmaceutical composition comprising a combination of dextro and laevo isomers of sotalol	(P-I) (TRC-303)	2001111808	2213560	Russia
109	Pharmaceutical composition comprising a combination of Dextro-And-Laevo Isomers of Sotalol	(P-I) (TRC-303)	2102291	1041206	Hongkong
110	Pharmaceutical composition comprising a combination of Dextro-And Laevo-Isomers of Sotalol	(P-I) (TRC-303)	Validated	Validation of EP1146865	Austria
111	Pharmaceutical composition comprising a combination of Dextro-And Laevo-Isomers of Sotalol	(P-I) (TRC-303)	Validated	Validation of EP1146865	Belgium
112	Pharmaceutical composition comprising a combination of Dextro-And Laevo-Isomers of Sotalol	(P-I) (TRC-303)	Validated	Validation of EP1146865	Denmark
113	Pharmaceutical composition comprising a combination of Dextro-And Laevo-Isomers of Sotalol	(P-I) (TRC-303)	Validated	Validation of EP1146865	Finland

114	Pharmaceutical composition comprising a combination of Dextro-And Laevo-Isomers of Sotalol	(P-I) (TRC-303)	Validated	Validation of EP1146865	France
115	Pharmaceutical composition comprising a combination of Dextro-And Laevo-Isomers of Sotalol	(P-I) (TRC-303)	Validated	Validation of EP1146865	Germany
116	Pharmaceutical composition comprising a combination of Dextro-And Laevo-Isomers of Sotalol	(P-I) (TRC-303)	Validated	Validation of EP1146865	Greece
117	Pharmaceutical composition comprising a combination of Dextro-And Laevo-Isomers of Sotalol	(P-I) (TRC-303)	Validated	Validation of EP1146865	Ireland
118	Pharmaceutical composition comprising a combination of Dextro-And Laevo-Isomers of Sotalol	(P-I) (TRC-303)	Validated	Validation of EP1146865	Italy
119	Pharmaceutical composition comprising a combination of Dextro-And Laevo-Isomers of Sotalol	(P-I) (TRC-303)	Validated	Validation of EP1146865	Netherlands
120	Pharmaceutical composition comprising a combination of Dextro-And Laevo-Isomers of Sotalol	(P-I) (TRC-303)	Validated	Validation of EP1146865	Portugal
121	Pharmaceutical composition comprising a combination of Dextro-And Laevo-Isomers of Sotalol	(P-I) (TRC-303)	Validated	Validation of EP1146865	Spain
122	Pharmaceutical composition comprising a combination of Dextro-And Laevo-Isomers of Sotalol	(P-I) (TRC-303)	Validated	Validation of EP1146865	Sweden
123	Pharmaceutical composition comprising a combination of Dextro-And Laevo-Isomers of Sotalol	(P-I) (TRC-303)	Validated	Validation of EP1146865	Switzerland
124	Pharmaceutical composition comprising a combination of Dextro-And Laevo-Isomers of Sotalol	(P-I) (TRC-303)	Validated	Validation of EP1146865	United Kingdom
125	2-Propene-1-ones as HSP 70 Inducers	P-6	2007-507931	4790704	Japan
126	2-Propene-1-ones as HSP 70 Inducers	P-6	2562130	2562130	Canada
127	2-Propene-1-ones as HSP 70 Inducers	P-6	PA/a/2006/011770	277083	Mexico
128	2-Propene-1-ones as HSP 70 Inducers	P-6	2005232159	2005232159	Australia
129	2-Propene-1-ones as HSP 70 Inducers	P-6	2006/08077	2006/08077	South Africa
130	2-Propene-1-ones as HSP 70 Inducers	P-6	2006139940	2341522	Russia
131	2-Propene-1-ones as HSP 70 Inducers	P-6	7023669/ 2006	825492	Korea
132	Thiazolinones and Oxazolinones and their use as PTP 1B Inhibitors	P-10	11/992,016	Allownace fee not paid	USA
133	Thiazolinones and Oxazolinones and their use as PTP 1B Inhibitors	P-10	2008/02078	2008/02078	South Africa
134	Novel Dual Action Receptor Antagonists (DARA) at the ATI and ETA Receptors	P-12	1913/MUMNP/2008	251554	India
135	Novel Dual Action Receptor Antagonists (DARA) at the AT1 and ETA Receptors	P-12	2007221495	No not received	Australia
136	Novel Dual Action Receptor Antagonists (DARA) at the ATI and ETA Receptors	P-12	2008139321	2425833	Russia
137	Novel Compounds for Treatment of Obesity	P-15	857/ KOL/ 2007	254907	India
138	Novel Compounds for Treatment of Obesity	P-15	P080102438	066155	Argentina
139	Novel Compounds for Treatment of Obesity	P-15	97121081	1360541	Taiwan
140	Novel Compounds for Treatment of Obesity	P-15	12/224,168	8143424	USA
141	Novel Compounds for Treatment of Obesity	P-15	13/346968	83,78,118	USA
142	Novel Compounds for Treatment of Obesity	P-15	8772567.7	2061766	Europe

143	Novel Compounds for Treatment of Obesity	P-15	9106665.2	1129221	Hongkong
144	Novel Compounds	P-15	202515	202515	Israel
145	Novel Compounds	P-15	MX/A/2009/013070	291555	Mexico
146	Novel Compounds	P-15	26,98,704	2698704	Canada
147	Novel Compounds	P-15	W-00200903408	000035174	Indonesia
148	Novel Compounds	P-15	2009/08760	2009/08760	South Africa
149	Novel Compounds	P-15	2008259314	2008259314	Australia
150	Novel Thyroid like compounds useful for the treatment of Metabolic diseases	P-15	200901651	019084	Russia
151	Novel Compounds	P-15	200908029-2	157502	Singapore
152	Novel Compounds	P-15	2010-510961	5243537	Japan
153	Novel Compounds	P-15	1-2009-502329	I-2009-502329	Philippines
154	Novel Compounds	P-15	IAP20090407	IAP 04485	UZBEKISTAN
155	Novel Thyroid like Compounds	P-15	582273	582273	New Zealand
156	Novel Compounds	P-15	10-2010-7000236	1152965	Korea
157	Novel Compounds	P-15	A200913974	98962	Ukraine
158	Novel Compounds	P-15	200880102100.8	101772487	China
159	Novel Compounds	P-15	'08772567.7	Validation of EP101772487	Austria
160	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Belgium
161	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Bulgaria
162	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Cyprus
163	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Czech
164	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Estonia
165	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Spain
166	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Finland
167	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Greece
168	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Hungary
169	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Italy
170	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Lithuania
171	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Norway

172	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Poland
173	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Portugal
174	Novel Compounds	P-15	08772567.7	Validation of EP101772487	romania
175	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Slovakia
176	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Turkey
177	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Bosnia & Herzegovnia
178	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Serbia
179	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Albania
180	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Croatia
181	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Denmark
182	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Iceland
183	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Latvia
184	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Netherlands
185	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Slovenia
186	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Sweden
187	Novel Compounds	P-15	08772567.7	Validation of EP101772487	France
188	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Germany
189	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Ireland
190	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Luxembourg
191	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Monaco
192	Novel Compounds	P-15	08772567.7	Validation of EP101772487	Malta

193	Novel Compounds	P-15	Switz is included Liechtenstein	Validation of EP101772487	Switzerland
194	Novel Compounds	P-15	08772567.7	Validation of EP101772487	United Kingdom
195	Low Dose Pharmaceutical Composition	P-16 IBD	11201509275P	To be recd	Singapore
196	Low Dose Pharmaceutical Composition	P-16 IBD	14/890,131	.9,610,247	USA
197	NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES	P-16	12/ 877,704	85,41,430	USA
198	NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES	P-16	13/963,160	88,22,484	USA
199	NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES	P-16	099129121	1500623	Taiwan
200	FUSED THIAZOLO AND OXAZOLO PYRIMIDONES	P-16	2764/KOLNP/2011	275790	India
201	FUSED THIAZOLO AND OXAZOLO PYRIMIDONES	P-16	201080038159.2	201080038159 2	China
202	Fused Thiazolo and Oxazolo Pyrimidinones	P-16	598020	598020	New Zealand
203	Fused Thiazolo and Oxazolo Pyrimidinones	P-16	2010307984	2010307984	Australia
204	Fused Thiazolo and Oxazolo Pyrimidinones	P-16	10-2012-7011052	1710430	Korea
205	Fused Thiazolo and Oxazolo Pyrimidinones	P-16	MX/A/2012/004074	311790	MEXICO
206	Fused Thiazolo and Oxazolo Pyrimidinones	P-16	2012-533740	5681195	Japan
207	Fused Thiazolo and Oxazolo Pyrimidinones	P-16	201205825	107473	Ukraine
208	Fused Thiazolo and Oxazolo Pyrimidinones	P-16	201270556	20,228	Eurasia
209	Fused Thiazolo and Oxazolo Pyrimidinones	P-16	219116	219116	Israel
210	Fused Thiazolo and Oxazolo Pyrimidinones	P-16	W00201201387	000044768	Indonesia
211	Fused Thiazolo and Oxazolo Pyrimidinones	P-16	201202466-7	179845	Singapore
212	Fused Thiazolo and Oxazolo Pyrimidinones	P-16	2012/03262	2012/03262	South Africa
213	Fused Thiazolo and Oxazolo Pyrimidinones	P-16	1-2012-500704	1-2012-500704	Philippines
214	Fused Thiazolo and Oxazolo Pyrimidinones	P-16	2012001679	MY-157629-A	Malaysia
215	Benzofuroxan derivatives and their use in treating angina pectoris	NO Donors	99918219.9	1080081	Europe
216	Process for the preparation of novel benzofuroxan derivatives	NO Donors	935/CAL/98	188837	India
217	Process for preparation of novel benzofuroxan derivatives	NO Donors	462/CAL/99	188837	India
218	Novel benzofuroxan derivatives, and their pharmaceutical compositions	NO Donors	303/CAL/2000	203790	India
219	A process for preparation of benzofuroxan derivatives	No Donors	40/CAL/2002	190509	India
220	A process for preparation of benzofuroxan derivatives	No Donors	41/CAL/2002	192593	India
221	A process for preparation of 5(6)-[(2,3- dihydroxy propyloxy) carbonyl] benzofuroxan derivatives	No Donors	42/CAL/2002	190510	India
222	A process for the preparation of 5(6)- carboethoxynicotinamide benzofuroxan	NO Donors	478/CAL/2002	192420	India

223	Benzofuroxan derivatives and therapeutic agents for angina pectoris containing the same	NO Donors	2000-550836	3738239	Japan
224	Compounds of the Benzofuroxan series, a process for preparing thereof (variants), a pharmaceutical composition, a procedss for preparing a parenteral formulation and a method for the treatment of coronary heart diseases	NO Donors	2000132204	2222532	Russia
225	Novel benzofuroxan derivatives, their preparation, pharmaceutical composition and their therapeutic uses	NO Donors	09/565917	6248895	USA
226	Benzofuroxan derivatives, their therapeutic uses and pharmaceutical compositions	NO Donors	09 / 690805	6232331	USA
227	Benzofuroxan derivatives and their use in treating angina pectoris	NO Donors	Validation of EP1080081	Validation completed	Austria
228	Benzofuroxan derivatives and their use in treating angina pectoris	NO Donors	Validation of EP1080081	Validation completed	Belgium
229	Benzofuroxan derivatives and their use in treating angina pectoris	NO Donors	Validation of EP1080081	Validation completed	Denmark
230	Benzofuroxan derivatives and their use in treating angina pectoris	NO Donors	Validation of EP1080081	Validation completed	Finland
231	Benzofuroxan derivatives and their use in treating angina pectoris	NO Donors	Validation of EP1080081	Validation completed	France
232	Benzofuroxan derivatives and their use in treating angina pectoris	NO Donors	Validation of EP1080081	Validation completed	Germany
233	Benzofuroxan derivatives and their use in treating angina pectoris	NO Donors	Validation of EP1080081	3050550	Greece
234	Benzofuroxan derivatives and their use in treating angina pectoris	NO Donors	Validation of EP1080081	Validation completed	Ireland
235	Benzofuroxan derivatives and their use in treating angina pectoris	NO Donors	Validation of EP1080081	Validation completed	Italy
236	Benzofuroxan derivatives and their use in treating angina pectoris	NO Donors	Validation of EP1080081	Validation completed	Netherlands
237	Benzofuroxan derivatives and their use in treating angina pectoris	NO Donors	Validation of EP1080081	Validation completed	Portugal
238	Benzofuroxan derivatives and their use in treating angina pectoris	NO Donors	Validation of EP1080081	Validation completed.	Spain
239	Benzofuroxan derivatives and their use in treating angina pectoris	NO Donors	Validation of EP1080081	Validation completed	Sweden
240	Benzofuroxan derivatives and their use in treating angina pectoris	NO Donors	Validation of EP1080081	Validation completed	Switzerland / Liechtenstein
241	Benzofuroxan derivatives and their use in treating angina pectoris	NO Donors	Validation of EP1080081	Validation completed	United Kingdom
242	Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors	P8	2003214534	2003214534	Australia
243	Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors	P8	1580/KOLNP/2004	6232331	India
244	Novel compounds and therapeutic uses thereof	P8	60/370,224	7138416	USA
245	Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors	P8	274708704592186	2004/7295	South Africa